Introduction
The PI3K/Akt/mTOR signaling pathway plays a critical role in cell growth, survival, and metabolism (1) . Its aberrant activation, either by mutations of the PIK3CA gene, loss of PTEN expression or amplification/mutation of upstream receptor tyrosine kinases (RTK), is frequent in human cancers and may drive tumor growth as well as limit sensitivity to targeted therapies (2) (3) (4) (5) (6) (7) . Therefore, pharmacologic inhibitors of the PI3K/Akt/mTOR pathway are entering the clinic at a rapid pace. Although early-phase clinical studies have shown that a subset of patients derives benefit from treatment with these agents, a number of factors could potentially limit their clinical activity. These include treatment of diagnostically unselected patient populations, insufficient target inhibition, and/or the activation of compensatory pathways leading to resistance (8) (9) (10) (11) . Therefore, approaches are needed that enable a comprehensive measurement of both target inhibition and activation of compensatory pathways in tumors treated with a targeted therapy that can be translated to the clinical setting (12) . In addition, there is a need to identify the dose and schedule for each agent that result in meaningful target and pathway inhibition in patients. These parameters would have clear implications for the clinical development of targeted therapies, and for future rational combination strategies to improve efficacy.
Among the different nodes in the PI3K/Akt/mTOR pathway, Akt1/2/3 occupy a central hub with distinct cellular functions (13) , and their pharmacologic blockade downregulates signaling mediated by diverse upstream activating events (14) . Two classes of inhibitors are currently in clinical development: catalytic, ATP-competitive inhibitors (such as GDC-0068) that preferentially target the active kinase, and allosteric inhibitors (such as MK-2206) that bind to the Akt plekstrin-homology domain, resulting in a conformational change that prevents Akt membrane localization and subsequent activation (15, 16) . GDC-0068, a potent, orally bioavailable, selective pan-Akt inhibitor, was identified by structure-guided drug design (17) . The enzymatic IC 50 values of GDC-0068 range from 5 to 30 nmol/L for the three isoforms of Akt (18) . Cancer cell lines with activated Akt signaling (e.g., via PTEN loss, PIK3CA mutations or ERBB2 amplification) are sensitive to Akt inhibition (19, 20) . The preferential binding of GDC-0068 to the active conformation of Akt likely contributes to this enhanced sensitivity (21) .
To identify pharmacodynamic biomarkers that measure the optimal inhibitory effects of GDC-0068 in cell lines and xenograft models, we used a reverse-phase protein array (RPPA) platform (22) to conduct a focused search within a panel of 100 validated proteins involved in oncogenic signaling pathways. We identified ten phosphoproteins that constituted a set of core biomarkers of GDC-0068 pharmacologic activity. The coordinate regulation of these biomarkers in tumor cells from patients treated with GDC-0068 confirmed substantial Akt pathway suppression at welltolerated doses in a phase I study. The identification of biologically active doses of GDC-0068 has enabled the design of rational starting doses for phase Ib combination trials. In addition, we observed increased feedback activation of HER3 and ERK in clinical samples following GDC-0068 treatment, providing clinical validation of results from tumor models (23, 24) . This approach could therefore be used to monitor pharmacodynamic response to targeted therapy in tumor biopsies and lead to rational drug combinations.
Materials and Methods
Cell lines, cell culture, and treatments All cell lines were purchased from American Type Culture Collection and cultured as described in its database. The trastuzumab-resistant cell line BT474-Tr was obtained by chronic exposure to trastuzumab as described (25) . GDC-0068 was provided by Genentech and rapamycin was purchased at Sigma. For in vitro experiments, both reagents were diluted in dimethyl sulfoxide (DMSO).
Reverse phase protein arrays
Cell and xenograft tumor samples were directly lysed in T-PER (PIERCE) based lysis buffer containing protease inhibitors and phosphatase inhibitors. Paired (pre-and posttreatment) tumor biopsies from patients were flash-frozen in optimum cutting temperature (OCT formulation, Sakura Finetek) and sectioned to 6 mm. Proteins were extracted from the tissue sections with T-PER-based lysis buffer and combined for the assay. Protein lysates were printed on nitrocellulose-coated glass slides, with each sample spotted on four different locations. A set of assay control samples was also printed on each slide. Total protein concentration in each spot was assessed by Sypro staining. The slides were blocked and then stained against 100 total protein and phospho-specific RPPA-validated antibodies. The intensity of specific antibody staining was subtracted from the intensity of secondary antibody alone and was then normalized to total protein concentrations. The specific intensity is normalized to the median intensity of all signals on the slides to remove potential spatial effects. For methods and overview of RPPA, see ref. (26) .
For more information on Western blot analysis and immunohistochemistry (IHC), see Supplementary information.
Tumor models
Mice were maintained and treated in accordance with institutional guidelines of Vall d'Hebron University Hospital or Genentech Institutional Animal Care and Use Committee. Six-week-old female athymic nude-Foxn1 nu mice were purchased from Harlan Laboratories or NCR nude female mice from Taconic. Mice were housed in air-filtered laminar flow cabinets with a 12-hour light cycle and food and water ad libitum. Mice were handled with aseptic procedures and allowed to acclimatize to local conditions for 1 week before the experimental manipulations. A 17b-estradiol pellet (Innovative Research of America) was implanted subcutaneously into each mouse 1 day before cell injection of BT474-Tr cells. A total of 10 7 BT474-Tr or PC3 cells were resuspended in PBS and injected subcutaneously into the right flank of each mouse in 200 mL of final volume. Treatments began when tumors reached an average size of 125 to 350 mm 3 and were thus considered as established
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, where x is mean tumor volume.
Patient samples
Patients included in the dose escalation NCT01090960 trial were biopsied before treatment initiation (pre) and after 2/3 weeks of receiving GDC-0068 (Post). Two 18G core biopsies were taken at each time point. One corebiopsy was immediately embedded in OCT and snap-frozen for RPPA analysis. The second core-biopsy was formalin fixed and paraffin-embedded for IHC studies. Frozen biopsies in OCT were sectioned at 6 mm thickness, and each section was stained briefly with hematoxylin to identify the historical features. Tumor cells or adjacent stromal cells were laser-captured separately before processing for the RPPA on an Arcturus LCM workstation (Life Technologies). The mutation status was determined as in ref. (27) .
Statistical analysis
The RPPA data were processed using Partek Genomic Suite 6.5 (Partek Inc.). Specific intensity data were log transformed and significant changes in protein levels in each cell line were tested with two-way ANOVA, considering the treatment time and concentration. The significant changes in all cell lines were tested by three-way ANOVA taking into account cell line, time, and concentration of treatment. For the RPPA data from in vivo models and clinical biopsies, two-way ANOVA was used to identify the differences in subject (mouse or patient) and treatment effects. The significant changes were defined as more than 1.6-fold with adjusted P < 0.05. The false discovery rate (FDR) was controlled by adjusting the P values with the step up method (28) .
The Dunnett test was used to calculate significance for xenograft TGI data.
The Kruskal-Wallis test was used to assess immunohistochemical expression differences between treatment groups. P values of <0.05 were considered significant. Data were processed using PASW Statistics v17.
Results

Biomarkers of catalytic AKT inhibition and cell survival
To identify molecular biomarkers of catalytic Akt inhibition, we used RPPA to analyze the effects of the Akt inhibitor GDC-0068 on the primary endothelial cell line (HuVEC), and three tumor cell lines with activated PI3K-pathway signaling (MCF-7, PC-3, and U87; Fig. 1A and Supplementary Table S1). One hundred total protein and phospho-specific antibodies of proteins, all of them previously validated in the RPPA platform and broadly representing the major oncogenic pathways, were evaluated. The platform allowed quadruple measurements of all endpoints in multiple dilutions in a single experiment. The multiple RPPA measurements enabled analysis of variance (ANOVA) determination across the concentration-dependent inhibition profiles. Throughout the experiments, we observed that changes above 1.6-fold over the mean of the control group were consistently 2-fold above the highest SD of control signals across all technical repeats. Therefore, the significant change was defined as more than 1.6-fold changes over the mean control group with an FDR adjusted P value of <0.05. In this unbiased analysis, a set of ten biomarkers were consistently modulated in all cell lines and were thus taken to constitute a core biomarker set of catalytic Akt inhibition ( Fig. 1B and Supplementary Table  S2 ). Among them, Akt S473, Akt T308, and PRAS40 T246 phosphorylation levels were found to be regulated at the lowest concentration of GDC-0068 tested (0.01 mmol/L) after 3-hour treatment in all four cell lines. Phosphorylation of Akt (S473 and T308) increased after treatment with GDC-0068, an event previously described for ATP competitive Akt inhibitors (17, 29) . The modulation of pAkt and pPRAS40, together with other proteins comprising the biomarker signature of Akt inhibition, showed similar dose-dependent effects by Western blot analysis at both 6 and 48 hours in the three cancer cell lines analyzed by RPPA as well as in breast cancer cell lines without intrinsic activation of the PI3K pathway (Fig. 1C , Supplementary  Fig. S1 , and data not shown). The effects observed on the majority of the biomarkers comprising the signature were comparable by RPPA and Western blot analyses but certain biomarkers, such as eIF4G and mTOR, were more clearly dephosphorylated in the RPPA analyses. By placing these identified biomarkers in the context of known biochemical interactions of the Akt pathway, our approach reveals that GDC-0068 causes both accumulation of pAkt due to inhibitor-induced stabilization of an Akt active-like conformation that restricts phosphatase accessibility (17, 29) , as well as a decrease in the phosphorylation of several direct Akt substrates i.e., PRAS40, GSK3b, mTOR, eIF4G, ATP citrate lyase, and FOXO3a (Fig. 1D) . Downstream of mTOR, we also observed a profound reduction of phosphorylated ribosomal protein S6 (pS6). We conclude that this group of proteins constitutes the main effectors of pharmacologic Akt inhibition by GDC-0068.
We next examined the modulation of the 100 biomarker panel in relation to the survival of cells treated with GDC-0068 at 3 and 24 hours posttreatment. Pearson (linear) and Spearman (nonlinear) correlations of the individual biomarkers revealed that each cell line was represented by a distinct biomarker set, but the core 10-biomarkers were represented across all cell lines (Supplementary Table S3 ). We next queried whether the 10-biomarker set correlated with cell survival in each cell line upon treatment with GDC-0068 (30) , for which the RPPA data was subjected to principal component analysis (PCA), providing a lowdimension representation of the biomarkers in response to the treatment ( Supplementary Fig. S2A ). The PCA biomarker profile derived from the ten core markers was distinct for each cell line and correlated well to fractional survival even though each cell line responded differently to GDC-0068 ( Supplementary Fig. S2B ). These results collectively suggest that the 10 core markers reflect the main biologic effect of GDC-0068 in modulating cell survival in a cell-specific manner.
Selective effects on cell signaling by Akt inhibition with GDC-0068
The broad proteomic profiling approach allows a detailed characterization of the pharmacodynamic consequences of Akt inhibition. To test the specificity of our biomarker set, we compared it with the one elicited by allosteric mTORC1 inhibition. For this comparison, we chose rapamycin since mTOR is a clinically validated target. The phosphorylation events significantly regulated in all four cell lines by either agent or by both agents are depicted in Fig. 2A . Both GDC-0068 and rapamycin inhibited the common Akt effectors mTOR, eIF4G, and S6 proteins. However, GDC-0068 additionally modulated pFOXO3a, pGSK3b, and pATP citrate lyase levels, highlighting the prominent role of Akt in regulating the survival response to the metabolic state of tumor cells.
In addition, this 100-biomarker RPPA profiling following GDC-0068 treatment revealed feedback activation of HER3 and ERK signaling following Akt blockade at early time points after exposure (Fig. 2B) . Increased expression and phosphorylation of HER3 after treatment with GDC-0068 were confirmed by Western blotting (Fig. 2C) . The observed crosstalk in signaling pathways and activation of upstream signaling following Akt inhibition by GDC-0068 is consistent with observations with other PI3K/Akt/mTOR inhibitors (23, 24) . The specific modulation of Akt T308 and S473 by GDC-0068 was not coincident with the previously observed feedback activation of Akt following rapamycin treatment, with the latter occurring at later time points (48 hours after exposure, data not shown; refs. 17, 31). Thus, RPPA analyses enabled the characterization of specific downstream signaling effects associated with the inhibition of Akt by GDC-0068 and, furthermore, enabled the characterization of feedback upregulation, providing support for rational combination strategies.
In vivo dose responsive inhibition of core biomarkers by GDC-0068 and correlation with tumor response
In preparation for the clinical evaluation of GDC-0068, we studied the effects of Akt inhibition in cancer cell xenografts treated with GDC-0068. Catalytic Akt inhibition resulted in dose-dependent tumor growth inhibition in two xenograft models with increased PI3K pathway activity, ERBB2-amplified, PIK3CA-mutant BT474-Tr, and PTENnull PC3 (Fig. 3A) . We first interrogated the dose-dependent modulation of the three biomarkers that were most significantly correlated to GDC-0068 dosing and in vitro antiproliferative response in the BT474-Tr xenograft model (Fig.  3B, Supplementary Fig. S3 , and data not shown). pAkt T308 and S473 levels were significantly enhanced at the two highest doses (22 and 88 mg/kg) across all time points studied (namely, three time points after the third daily dose and one time point after 18 days). Although PRAS40 T246 also showed a dose-dependent pharmacodynamic modulation, in contrast to pAkt, it also showed a time-dependent modulation, with greater inhibition at earlier time points after drug administration (Supplementary Fig. S3 ). These observations support the importance of appropriate selection of time points for optimal clinical biopsy collection (i.e., 2-4 hours following compound administration) and highlight the potential importance of dose and schedule with this compound.
Analyses of the tumors by RPPA revealed that a set of 19 biomarkers was significantly, dose-dependently modulated by GDC-0068 in the BT474-Tr model (Fig. 3C) . Eight of these were present in the in vitro-derived core biomarker set shown in Supplementary Table S2 (pATP citrate lyase and pS6 S235 were not tested). Several phosphorylation events in the Ras/Raf/MEK/ERK pathway showed distinct regulatory patterns culminating in the upregulation of Erk T202/Y204. Furthermore, consistent with our in vitro data, dose-dependent upregulation of HER3 was also observed (Fig. 3C ). These data demonstrate that GDC-0068 significantly modulates the Akt pathway in vivo, as well as elicited feedback activation of the HER3 and ERK pathways. The quantitative nature of RPPA measurements made it possible to assess the relationship between biomarker changes and both dose of treatment and tumor growth inhibition. Because of the complex relationship between individual markers and inhibition of tumor growth, we used a biomarker model based on the PCA scores for the ten core biomarkers that we had identified in vitro (Fig. 1D and Supplementary Fig. S2 ). The in vivo BT474-Tr and PC3 models showed similar biomarker behavior (Fig. 3D , PCA loading profiles) as well as significant correlation between the biomarker set score (PCA score) and tumor growth inhibition (%TGI). Consistent with our results in vitro, the core biomarkers reflect the effect of GDC-0068 on tumor growth in vivo. The PCA model thus provides a holistic approach to characterize the correlation between quantitative changes in core biomarkers and tumor growth inhibition.
Modulation of biomarkers of Akt inhibition in tumors from patients treated with GDC-0068
As part of the first in human phase I clinical trial of GDC-0068 in patients with advanced solid tumors (NCT01090960; ref. 32 ), we incorporated a number of prespecified on-study tumor biopsies to determine the clinical feasibility of inhibiting Akt at levels that correlated with growth inhibition in preclinical models. Tumor biopsies were obtained pre-treatment and 2 to 4 hours post treatment after 8 to 15 days of continuous daily dosing starting from the 100 mg/day dose cohort, which achieved equivalent plasma exposures to the 12.5 mg/kg dose in mouse xenograft models (Fig. 3A) . We carried out RPPA analyses on protein lysates from paired pretreatment and on-treatment biopsies taken between 2 and 4 hours post-dose after 8 to 15 days of continuous daily dosing. Figure 4A and B show the RPPA analysis from a total of 9 patients within the 100, 200, and 400 mg/day GDC-0068 dose cohorts, which were all welltolerated doses (32) . Analysis of the on-treatment biopsies showed a marked increase of Akt S473 and decrease of PRAS40 T246 in patients dosed as low as 100 mg/day. The modulation of Akt S473 and PRAS40 T246 was confirmed by IHC in available patient samples from an independent, concurrent biopsy ( Fig. 4C and D) . A potential correlation between tumor genotype (PTEN/PIK3CA status) and pharmacodynamic effect was not observed and also not expected, given the preclinical data demonstrating pathway inhibition in both PI3K-activated and non-PI3K-activated models (Supplementary Table S4 ).
The high degree of necrosis in the PTEN-null samples #301 and #402 (rising from 0% in the pretreatment biopsies to as high as 30% and 90% for #301 and #402, respectively) likely contributed to the apparent lack of PRAS40 T246 modulation observed by RPPA (Fig. 4B) . . GDC-0068 modulated Akt signaling in tumors from patients. RPPA revealed significant modulation of (A) Akt S473 and (B) PRAS40 T246 in tumor biopsies from patients with cancer treated with GDC-0068 at three dose escalation levels (100, 200, and 400 mg/day). Tumor core biopsies from pretreatment (pre, blue) and 15 to 22 days posttreatment (post, red) were assayed in four dilutions of tumor lysates. All the technical replicates were plotted as normalized intensities to the mean pretreatment. C, modulation of pAkt S473 and (D) of PRAS40 T246 in tumor biopsies from representative patients treated with 100, 200, and 400 mg daily dose (post) as compared with the PRAS40 T246 levels in predose tumor biopsy. H-Score quantification is provided. Arrows indicate stroma.
As there was significant variation in the percentage of tumor tissue in biopsies, which limited our ability to interpret the RPPA data, we used laser-capture microdissection (LCM) to enrich for tumor cells before RPPA analysis in all patients from the 100 mg cohort, where sufficient material remained for LCM in paired pre-and post-treatment tumor biopsies. We first compared the biomarker modulation in tumor versus nontumor samples. While changes in Akt S473 and Akt T308 expression were present in both epithelial tumor and stromal compartments, PRAS40 T246 was modulated uniquely in epithelial tumor cells, in accordance with what was observed by immunohistochemical staining, underscoring the need to enrich for the tumor cell population (Fig.  5A, Fig. 4C and D, arrows and data not shown). In addition, increased levels of HER3 following GDC-0068 treatment was detected only in tumor cells of the breast tumor biopsy of patient 301 and not in the stromal component (Fig. 5A) . The dose of 100 mg/day GDC-0068 showed substantial coordinate modulation of the GDC-0068 biomarker core in epithelial tumor cells in all three patients (Fig. 5B) . Even though the percentage change of markers varied from patient to patient, the average levels of pAkt increased significantly over pretreatment levels, and the 8 other core markers were inhibited in the range of 41% to 69%, with an average of 56% inhibition (Fig.  5B and Supplementary Table S5 ). In addition, GDC-0068 elicited compensatory HER3 and ERK activation in tumors from 2 patients. These results demonstrated that GDC-0068 engaged the target and significantly inhibited signaling downstream of Akt in patient tumor samples starting from as low as the 100 mg daily dose.
To test whether the degree of pathway inhibition observed in patients is biologically meaningful, we compared the pattern of the inhibition of the core biomarkers from patients with those derived from cell lines and xenografts. Unsupervised clustering of the RPPA data from all three sources showed that patients' data were closely clustered with xenograft data (Supplementary Fig. S4 ). We further questioned if our comprehensive approach provided any advantage over utilizing a consistently inhibited protein such as PRAS40 T246. We compared a single-biomarker TGI projection to the biomarker set projection using PCA-scores (Supplementary Table S6 ). The individual projections were not only highly variable but also differ substantially from the PCA score-based projected TGI. Therefore, we propose that using a comprehensive pharmacodynamic assessment provides a more robust readout of pathway inhibition in a tumor sample than a single biomarker approach. This approach may be critically important in clinical contexts in which both drug dose and genetic background are variables. We finally applied the xenograft-derived PCA models (Fig. 3D) to estimate the corresponding tumor growth inhibition (TGI; Table 1 based on the biomarker changes in the 100 mg cohort patients). The degree of pathway modulation in the 100 mg cohort patients was equivalent to changes leading to approximately 60% TGI in preclinical models. 
Discussion
Oncology drug discovery has increasingly focused on the development of targeted therapies, with considerable efforts to improve the specificity, safety, and efficacy of such agents. A core component of this strategy is the identification and evaluation of specific biomarkers that can functionally confirm target engagement and detailed pathway status at clinically meaningful doses in treated patients (33) .
In this work, we demonstrate that an unbiased screening of different in vitro and in vivo preclinical models, with 100 validated antibodies against total and activated proteins involved in oncogenic signaling pathways, led to the identification of core biomarkers for catalytic inhibition of Akt. RPPA is a sensitive platform to measure several dozens of phospho-epitopes from a few nanograms of protein extract and has utility for the quantitative analysis of on-treatment biopsies. However, a limitation of this technique is the variable percentage of malignant tissue present in the biopsy and the absence of a validated method of normalization for malignant epithelial cells. Because of this, immunohistochemistry can serve a valuable tool to confirm one or several biomarkers discovered by RPPA, but has limited multiplexing capacity. Our data show that it is possible to use LCM to isolate the cell population of interest and thus that LCM can be useful to overcome the challenge of sample heterogeneity. This technique was also highly informative in showing greater modulation of elements of the pathway in neoplastic cells relative to stromal cells, consistent with preclinical data showing that more dramatic effects are observed in tumor cell lines compared with normal cells. Although labor intensive, the powerful combination of LCM with the sensitive detection of RPPA is required for adequate assessment of target engagement specifically in the tumor tissue and offers a unique opportunity to study the molecular nature of tumor-stroma interactions in the clinical setting.
Our data show that the Akt pathway, as measured by multiple biomarkers, was modulated in three patients' tumors at a dose of 100 mg per day of GDC-0068. The degree of biomarker changes at the 100 mg dose was consistent with that observed in preclinical models with approximately 60% tumor growth inhibition. Lin and colleagues showed that GDC-0068 single-agent doses that exhibit 50% to 70% TGI result in tumor regressions when combined with docetaxel (21). We therefore considered the 100 mg GDC-0068 as a minimum dose that elicited biologic activity in patients and leveraged this knowledge to initiate phase Ib/II studies starting from this dose in combination with standard of care chemotherapies (i.e., docetaxel and mFOLFOX) and targeted agents (abiraterone), before reaching the single agent maximum tolerable dose of 600 mg daily (in regimen 21 days on/7 days off; refs. 34, 35) .
Our broader survey with RPPA also identified biomarkers that indicate upregulation of compensatory pathways. For example, HER3 phosphorylation and ERK activation following GDC-0068 treatment were detected in both preclinical models and, for the first time to our knowledge, in patient samples, demonstrating that previously reported compensatory mechanisms occur in a clinical setting (23, 24) . These findings have clear implications for the further development of rational combination therapies, for instance combining GDC-0068 with agents targeting HER3 or MEK.
In conclusion, we demonstrated that selected preclinical models could be used to effectively screen and identify a biomarker core of pathway modulation that was translatable to the clinic. RPPA following LCM was used to provide a broad profile of signaling pathway modulation in needle biopsies and confirmed robust pathway inhibition by GDC-0068. These findings demonstrate that GDC-0068 is inhibiting Akt, its intended mechanism of action, in tumor tissue at clinically achievable doses, and support its continued testing in diagnostically defined patient populations and with rational drug combinations. This approach can in principle be applied to other therapeutics to effectively provide the molecular foundation for subsequent stages of clinical development. NOTE: The PCA scores of the paired biopsies obtained from three 100-mg cohort patients were projected in two different xenograft models to predict the percentage of TGI. The PCA scores were derived from the core biomarkers in Fig. 5B and projected to the two models as in Fig. 3D .
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